Emcure Pharmaceuticals Ltd. (EMCURE) fundamentals
Emcure Pharmaceuticals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as EMCURE (ISIN INE168P01015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Emcure Pharmaceuticals Ltd. does
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.
Valuation and market data
| Last close | ₹1978.90 |
|---|---|
| Market capitalisation | ₹38,430 crore |
| Enterprise value | ₹39,255 crore |
| P/E (TTM) | 0.00 |
| Price to book | 8.28 |
| Price to sales (TTM) | 3.96 |
| Book value per share | ₹239.01 |
| Dividend yield | 18.19% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jul 10 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹5,453 crore | ₹944 crore | ₹733 crore | 0.00 |
| Mar 2025 | ₹4,524 crore | ₹428 crore | ₹317 crore | 16.95 |
| Mar 2024 | ₹3,636 crore | ₹200 crore | ₹161 crore | 8.89 |
| Mar 2023 | ₹3,232 crore | ₹212 crore | ₹160 crore | 8.85 |
| Mar 2022 | ₹3,520 crore | ₹616 crore | ₹447 crore | 24.71 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 77.8% |
|---|---|
| Foreign institutions (FII) | 4.9% |
| Mutual funds | 6.9% |
| Other domestic institutions | 1.6% |
| Retail and others | 8.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.